Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Investors back Infinity stock offer on new early data, surging PI3K interest

This article was originally published in Scrip

Executive Summary

With only early-stage data in hand for its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma IPI-145, Infinity Pharmaceuticals' recent $150 million common stock offering and response to preliminary Phase I results in hematological malignancies seems to reflect enthusiasm for PI3K inhibitors as a class - although the company says its findings so far show that it may have a class-leading therapeutic candidate.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC019773

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel